A study to examine cerebrospinal fluid transitivity and efficacy of afatinib in carcinomatous meningitis patients with non-small cell lung cancer patients harboring EGFR mutation.
Not Applicable
- Conditions
- carcinomatous meningitis patients with NSCLC harboring EGFR mutation
- Registration Number
- JPRN-UMIN000014065
- Lead Sponsor
- Kinki-Chuo Chest Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1. over Grade 2 of diarrhea, a severe gastrointestinal disorder 2. Interstitial lung disease 3. diagnose of malignancy in 5 years 4. Angina and myocardial infarction within six months, heart disorder, severe arrhythmia 5. pleural effusion or ascites which need treatment 6. uncontrolled complications 7. Serious drug allergy history 8. Cannot promise contraception 9. No pregnancy, during nursing 10. A chief physician decide not eligible
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cerebrospinal fluid transitivity of afatinib
- Secondary Outcome Measures
Name Time Method efficacy and safety of afatinib